Panion participates in Investor Day event, 29 November, in Odense, Denmark

Animal health is considered by many to be a future growth sector. Panion has advanced plans for listing the company as soon as possible.

Anja Holm will present information about the company's operations and business plans with respect to new forms of treatment of epilepsy in animals.

Panion is now working on a strategy for compiling existing knowledge and planning studies to be conducted in the next phase towards the launch of a drug for dogs. The company has contacted the relevant authorities to determine the specific requirements that are applicable to these studies.

Concurrently with the epilepsy project the company is working on several other concepts for new forms of treatment of animals.

NOVEMBER 14 2016

For further information, please contact:
Anja E. H. Holm, CEO
+ 45-22 94 66 00
[email protected]

The following documents can be retrieved from beQuoted
Panion Pressrelease 2016-11-14.pdf

The Company in brief
In June 2015 CombiGene formed a wholly owned subsidiary, then called CombiGene Vet AB, and in April 2016 the decision was taken to distribute the subsidiary to CombiGene's shareholders with the aim of listing the company. The company, which has been renamed Panion Animal Health AB, will use CombiGene's discoveries to develop a treatment for canine epilepsy. Panion Panion aims at inlicensing or acquiring other veterinary medicine projects or products.

If you want to open the text in your webbrowser click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected]

beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.

Vi hoppas att Du uppskattar denna service.